Press releases

Oxford BioTherapeutics Announces Receipt of a Milestone Payment as Boehringer Ingelheim Advances an Oncology Drug Candidate

Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076: An Experimental First in Class ADC Medicine for High Risk Her2 Negative Breast Cancer, Gastric, Lung, Bladder and Ovarian Cancer Patients - US Phase I Clinical Trial to be Initiated

Oxford BioTherapeutics Expands Strategic Collaboration with  WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

Oxford BioTherapeutics Appoints Chief Medical Officer, ​Abderrahim Fandi

Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors

Boehringer Ingelheim and Oxford BioTherapeutics Partnership Advances Second Oncology Drug Candidate into the Clinic

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics' WuXiBody® Platform

Kite and Oxford BioTherapeutics Establish Cell therapy Research Collaboration in Blood Cancers and Solid Tumours

Oxford BioTherapeutics  enters into Commercial License Agreement with Genmab

Oxford BioTherapeutics  Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates

Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022

Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT's Antibody Drug Conjugate OBT076 in Combination with Agenus CPI Balstilimab

Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology target

Oxford BioTherapeutics  Initiates Phase Ib Clinical Trial for OBT076 in Patients with Advanced Solid Tumours by Dosing First Patient in Combination with CPI Balstilimab in Europe ​

Oxford BioTherapeutics  and Boehringer Ingelheim Agree on 2 Year Extension to their Second Multi-Year Collaboration in Cancer Immunology

Oxford BioTherapeutics Announces Phase1b Trial in Collaboration with GORTEC to investigate OBT076 in Adenoid Cystic Carcinoma (ACC) of the Head and Neck

Oxford BioTherapeutics to Announce New Fully Integrated ADC Engine at the World ADC Conference 2023

Oxford BioTherapeutics  wins Tech Company of the Year and Special Recognition Award at Thames Valley SME Growth 100 Awards